Dermatological concerns for women and girls with turner syndrome.
dermatological manifestations
keloids
medical dermatology
onychodystrophy
quality of life
turner syndrome
xerosis cutis
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2023
2023
Historique:
received:
05
06
2023
accepted:
23
08
2023
medline:
2
10
2023
pubmed:
2
10
2023
entrez:
2
10
2023
Statut:
epublish
Résumé
Turner syndrome (TS) is associated with distinct manifestations in women and girls including short stature, cardiac abnormalities, premature ovarian failure as well as dermatological features, including lymphedema, keloids, onychodystrophy, and acne. Although many dermatological concerns present during the first few decades of life, the overwhelming majority of respondents are not provided with dermatology referrals at diagnosis. This cross-sectional study utilized an author designed survey to assess self-reported dermatological manifestations, dermatology referral experience, common therapies for select dermatological conditions, as well as a validated 10-question Dermatology Life Quality Index (DLQI) to assess quality-of-life impact in women and girls with Turner syndrome. In our cohort, 64% ( Our data reveal that skin conditions are highly prevalent in the TS population during the early decades of life and affirm utilizing these conditions in the TS diagnostic process, as well as emphasize the need for specialized dermatology referrals to address the detrimental impacts related to skin concerns on quality of life.
Identifiants
pubmed: 37780576
doi: 10.3389/fmed.2023.1235187
pmc: PMC10533914
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1235187Informations de copyright
Copyright © 2023 Rodriguez-Buritica, Mones, Prakash, Rivera, Aldrich, Rogge and Richardson.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Dermatology. 2001;202(1):1-3
pubmed: 11244219
JAMA Dermatol. 2015 Oct;151(10):1081-6
pubmed: 25928283
J Am Acad Dermatol. 2004 May;50(5):767-76
pubmed: 15097963
J Am Acad Dermatol. 2022 Aug;87(2):476-479
pubmed: 34688825
Ther Adv Endocrinol Metab. 2018 Jan;9(1):33-40
pubmed: 29344338
Eur J Endocrinol. 2021 Jan;184(1):79-88
pubmed: 33112259
J Am Acad Dermatol. 2019 Oct;81(4):963-969.e2
pubmed: 30586613
Pediatrics. 2005 Mar;115(3):732-5
pubmed: 15741379
Br J Dermatol. 1997 Oct;137(4):545-8
pubmed: 9390329
Arch Dermatol Res. 2014 Nov;306(9):803-8
pubmed: 25081927
Arch Dis Child. 2014 Jan;99(1):71-3
pubmed: 24064113
JAMA Dermatol. 2016 Apr;152(4):413-8
pubmed: 26934430
Int J Dermatol. 2012 Oct;51(10):1206-12
pubmed: 22458952
Lymphology. 2015 Sep;48(3):139-52
pubmed: 26939161
Clin Exp Dermatol. 1994 May;19(3):210-6
pubmed: 8033378
Eur J Endocrinol. 2017 Sep;177(3):G1-G70
pubmed: 28705803
Endocrinol Metab Clin North Am. 1991 Mar;20(1):121-52
pubmed: 2029883
J Invest Dermatol. 2014 Apr;134(4):1141-1142
pubmed: 24202232
Lancet. 1993 Jun 12;341(8859):1505-6
pubmed: 8099381
Endocr Rev. 2023 Jan 12;44(1):33-69
pubmed: 35695701
Am J Med Genet A. 2019 Oct;179(10):1987-2033
pubmed: 31418527
Br J Dermatol. 1998 Jun;138(6):993-7
pubmed: 9747360
JAMA Dermatol. 2017 Jul 1;153(7):666-674
pubmed: 28355423